Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

verubecestat

- PMLiVE

Merck and Proxygen partner in deal worth up to $2.5bn

The companies will identify molecular glue degraders against multiple therapeutic targets

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug associated with positive long-term health outcomes

A simulation model estimated lecanemab to potentially slow the rate of disease progression

- PMLiVE

Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer

It is estimated there will be around 66,000 new cases of uterine cancer in the US this year

- PMLiVE

Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test

If approved, the test could streamline the journey to diagnosis for more patients

- PMLiVE

Alzheimer’s Association report highlights need to improve patient-physician communication

Both individuals and primary care physicians reported a reluctance to address cognitive concerns

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration

US veterans in the early stages of the disease who meet VHA criteria will be eligible for coverage

- PMLiVE

Merck reports positive results for Keytruda combination in malignant pleural mesothelioma

The disease develops in the lungs and accounts for 75% of all cancerous mesothelioma cases

- PMLiVE

Merck signs $922m deal with Opko Health unit for Epstein-Barr vaccine candidate

There are no FDA approved vaccines for EBV, one of the most common human viruses

- PMLiVE

FDA approves intramuscular administration of Merck’s MMRV vaccines

Until now, the vaccines have only been administered via subcutaneous injection

- PMLiVE

FDA grants priority review for traditional approval of Biogen and Eisai’s Alzheimer’s drug

Leqembi was granted accelerated approval in the US earlier this year

- PMLiVE

Moderna/Merck’s skin cancer therapy given FDA breakthrough therapy designation

Nearly 325,000 new cases of melanoma were diagnosed globally in 2020

- PMLiVE

Merck and Ridgeback’s COVID-19 pill fails to prevent infection within households

Lagevrio is already approved to treat certain patients with COVID-19 in several markets

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links